Use of aromatase inhibitors in children and adolescents: What's new?

Current Opinion in Pediatrics

Volumn 22, Issue 4, 2010, Pages 501-507

  Diaz Thomas, Alicia ^a   Shulman, Dorothy ^a  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

anastrozole; aromatase inhibitors; letrozole; pediatrics; precocious puberty; short stature

Indexed keywords

ANASTROZOLE; BICALUTAMIDE; CALCIUM; CYPROTERONE ACETATE; ESTRADIOL; FOLLITROPIN; GONADOTROPIN; GROWTH HORMONE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LETROZOLE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LUTEINIZING HORMONE; METFORMIN; TAMOXIFEN; TESTOSTERONE; TESTOSTERONE ENANTATE; VITAMIN D; AROMATASE; AROMATASE INHIBITOR;

ALBRIGHT SYNDROME; BLEEDING; BODY HEIGHT; BONE AGE; BONE DENSITY; BONE GROWTH; BONE TURNOVER; CHONDRODYSPLASIA; DRUG EFFICACY; DRUG SAFETY; FAMILIAL MALE LIMITED PRECOCIOUS PUBERTY; GROWTH HORMONE DEFICIENCY; GYNECOMASTIA; HUMAN; INSULIN SENSITIVITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OVARY HYPERTROPHY; OVARY POLYCYSTIC DISEASE; PRECOCIOUS PUBERTY; PREDICTION; PRIORITY JOURNAL; REVIEW; SHORT STATURE; SIDE EFFECT; VIRILIZATION; VITAMIN SUPPLEMENTATION; ADOLESCENT; ADOLESCENT DEVELOPMENT; BLOOD; CHILD; CHILD DEVELOPMENT; DRUG EFFECTS; ENZYMOLOGY; FEMALE; GROWTH DISORDERS; MALE; PROGNOSIS; PUBERTY, PRECOCIOUS;

ADOLESCENT; ADOLESCENT DEVELOPMENT; AROMATASE; AROMATASE INHIBITORS; CHILD; CHILD DEVELOPMENT; FEMALE; GROWTH DISORDERS; HUMANS; MALE; PROGNOSIS; PUBERTY, PRECOCIOUS;

EID: 77955230698     PISSN: 10408703     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOP.0b013e32833ab888     Document Type: Review

References (44)

1. Mouridsen H, Giobbie-Hurder A, Goldhirsch A, et al. Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. N Engl J Med 2009; 361:766-776.
2. Gibson L, Lawrence D, Dawson C, Bliss J. Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women. Cochrane Database Syst Rev 2009; 7:CD003370.
3. Leschek WE, Jones J, Barnes KM, et al. Six-year results of spironolactone and testolactone treatment of familial male-limited precocious puberty with addition of deslorelin after central puberty onset. J Clin Endocrinol Metab 1999; 84:175-178.
4. Kreher NC, Pescovitz OH, Delameter P, et al. Treatment of familial malelimited precocious puberty with bicalutamide and anastrozole. J Pediatr 2006; 149:416-420.
5. Feuillan P, Calis K, Hill S, et al. Letrozole treatment of precocious puberty in girls with the McCune-Albright syndrome: a pilot study. J Clin Endocrinol Metab 2007; 92:2100-2106.
6. Mieszczak J, Lowe ES, Plourde P, Eugster EA. The aromatase inhibitor anastrozole is ineffective in the treatment of precocious puberty in girls with McCune-Albright syndrome. J Clin Endocrinol Metab 2008; 93:2751-2754.
7. Wickman S, Sipila I, Ankarberg-Lingren C, et al. A specific aromatase inhibitor and potential increase in adult height in boys with delayed puberty: a randomised controlled trial. Lancet 2001; 357:1743-1748.
8. Hero M, Norjavaara E, Dunkel L. Inhibition of estrogen biosynthesis with a potent aromatase inhibitor increases predicted adult height in boys with idiopathic short stature: a randomized controlled trial. J Clin Endocrinol Metab 2005; 90:6396-6402.
9. Hero M, Wickman S, Dunkel L. Treatment with the aromatase inhibitor letrozole during adolescence increases near-final height in boys with constitutional delay of puberty. Clin Endocrinol 2006; 64:510-513.
10. Mauras N, Gonzalez de Pijem L, Hsiang HY, et al. Anastrozole increases predicted adult height of short adolescent males treated with growth hormone: a randomized, placebo-controlled, multicenter trial for one to three years. J Clin Endocrinol Metab 2008; 93:823-831.
11. Plourde PV, Reiter EO, Jou HC, et al. Safety and efficacy of anastrozole for the treatment of pubertal gynecomastia: a randomized, double-blind, placebocontrolled trial. J Clin Endocrinol Metab 2004; 89:4428-4433.
12. Corbin CJ, Graham-Lorence S, McPhaul M, et al. Isolation of a full-length cDNA insert encoding human aromatase system cytochrome P-450 and its expression in nonsteroidogenic cells. Proc Natl Acad Sci 1988; 85:8948-8952.
13. Bulun SE, Sebastian S, Takayama K, et al. The human CYP19 (aromatase P450) gene: update on physiologic roles and genomic organization of promoters. J Steroid Biochem Mol Biol 2003; 86:219-224.
14. Santen RJ, Brodie H, Simpson R, et al. History of aromatase: saga of an important biologic mediator and therapeutic target. Endocr Rev 2009;30:343-375.
15. Jones ME, Boon WC, Proietto J, Simpson ER. Of mice and men: the evolving phenotype of aromatase deficiency. Trends Endocrinol Metab 2006; 17:55-64.
16. Morishima A,GrumbachMM, Simpson ER, et al. Aromatase deficiency in male and female siblings caused by a novel mutation and the physiological role of estrogens. J Clin Endocrinol Metab 1995; 80:3689-3698.
17. Eyssette-Guerreau S, Pinto G, Sultan A, et al. Effectiveness of anastrozole and cyproterone acetate in two brothers with familial male precocious puberty. J Pediatr Endocrinol Metab 2008; 21:995-1002.
18. Dixon JM, Renshaw L, Young O, et al. Letrozole suppresses plasma estradiol and estrone sulphate more completely than anastrozole in postmenopausal women with breast cancer. J Clin Oncol 2008; 26:1671-1676.
19. Geisler J, Helle H, Ekse D, et al. Letrozole is superior to anastrozole in suppressing breast cancer tissue and plasma estrogen levels. Clin Cancer Res 2008; 14:6330-6335.
20. Mauras N, Bishop K, Merinbaum D, et al. Pharmacokinetics and pharmacodynamics of anastrozole in pubertal boys with recent-onset gynecomastia. J Clin Endocrinol Metab 2009; 94:2975-2978.
21. Hero M, Toivianinen-Salo S, Wickman S, et al. Vertebral morphology in aromatase inhibitor treated males with idiopathic short stature or constitutional delay of puberty. J Bone and Mineral Res 2010 Feb 2 [Epub ahead of print].
22. Henry NL, Giles JT, Stearns V. Aromatase inhibitor-associated musculoskeletal symptoms: etiology and strategies for management. Oncology 2008; 22:1401-1408.
23. Bundred NJ. Aromatase inhibitors and bone health. Curr Opin Obstet Gynecol 2009; 21:60-67.
24. Hero M, Makitie O, Kroger H, et al. Impact of aromatase inhibitor therapy on bone turnover, cortical bone growth and vertebral morphology in pre and peripubertal boys with idiopathic short stature. Horm Res 2009; 71:290-297
25. Krishnan AV, Swami S, Peng L, et al. Tissue-selective regulation of aromatase expression by calcitriol: implications for breast cancer therapy. Endocrinology 2010; 151:32-42.
26. Hero M, Ankarberg-Lindgren C, Taskinen MR, et al. Blockade of oestrogen biosynthesis in peripubertal boys: effects on lipid metabolism, insulin sensitivity, and body composition. Eur J Endocrinol 2006; 155:453-460.
27. Melichar B, Kalabova H, Krcmova L, et al. Effect of aromatase inhibitors on lipid metabolism inflammatory response and antioxidant balance in patients with breast carcinoma. Anticancer Res 2009; 29:3337-3346.
28. Janni W, Hepp P. Adjuvant aromatase inhibitor therapy: outcomes and safety. Cancer Treat Rev 2010. [Epub ahead of print]
29. Rice S, Pellatt L, Ramanathan K, et al. Metformin inhibits aromatase via an extracellular signal-regulated kinase-mediated pathway. Endocrinology 2009; 150:4794-4801.
30. Rochira V, Zirilli L, Madeo B, et al. Testosterone action on erythropoiesis does not require its aromatization to estrogen: insights from the testosterone and estrogen treatment of two aromatase-deficient men. J Steroid Biochem Mol Biol 2009; 113:189-194.
31. Hero M, Wickman S, Hanhijarvi R, et al. Pubertal upregulation of erythropoiesis in boys is determined primarily by androgen. J Pediatr 2005; 146:245-252.
32. Ramasamy R, Ricci JA, Palermo GD, et al. Successful fertility treatment for Klinefelter's syndrome. J Urol 2009; 182:1108-1113.
33. Patry G, Jarvi K, Grober ED, Lo KC. Use of the aromatase inhibitor letrozole to treat male infertility. Fertil Steril 2009; 92:829 e1-829 e2.
34. Roth MY, Amory JK, Page ST. Treatment of male infertility secondary to morbid obesity. Nat Clin Pract Endocrinol Metab 2008; 4:415-419.
35. Mauras N, Bell J, Snow BG, et al. Sperm analysis in growth hormone-deficient adolescents previously treated with an aromatase inhibitor: comparison with normal controls. Fertil Steril 2005; 84:239-242.
36. Hill RA, Chua HK, Jones ME, et al. Estrogen deficiency results in apoptosis in the frontal cortex of adult female aromatase knockout mice. Mol Cell Neurosci 2009; 41:1-7.
37. Hill R, Pompolo S, Jones ME, et al. Estrogen deficiency leads to apoptosis in dopaminergic neurons in the medial preoptic area and arcuate nucleus of male mice. Mol Cell Neurosci 2004; 24:466-476.
38. Saldanha CJ, Duncan KA, Walters BJ. Neuroprotective actions of brain aromatase. Frontiers in Neuroendocrinology 2009; 30:106-118.
39. Spence RD, Zhen Y, White S, et al. Recovery of motor and cognitive function after cerebellar lesions in a songbird: role of estrogens. Eur J Neurosci 2009; 29:1225-1234.
40. Corbin CJ, Berger T, Ford JJ, et al. Porcine hypothalamic aromatase cytochrome P450: isoform characterization, sex-dependent activity, regional expression, and regulation by enzyme inhibition in neonatal boars. Biol Reprod 2009; 81:388-395.
41. Kil KE, Biegon A, Ding YS, et al. Synthesis and PET studies of [(11)Ccyano] letrozole (Femara), an aromatase inhibitor drug. Nucl Med Biol 2009; 36:215-223.
42. Ito K, Ito T, Okada T, et al. A case of brain metastases from breast cancer that responded to anastrozole monotherapy. Breast J 2009; 15:435-437.
43. Jenkins VA, Ambroisine LM, Atkins L, et al. Effects of anastrozole on cognitive performance in postmenopausal women: a randomized, double-blind chemoprevention trial (IBIS II). Lancet Oncol 2008; 9:953-961.
44. Young LA, Neiss MB, Samuels MH, et al. Cognition is not modified by large but temporary changes in sex hormones in men. J Clin Endocrinol Metab 2009; 95:280-288.